Back to top

Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market

Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Harrow, Inc. (HROW)